Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer

Creative Commons License

TASKOPARAN B., SEZA E. G., Demirkol S., TUNCER S., Stefek M., Gure A. O., ...More

CELLULAR ONCOLOGY, vol.40, no.6, pp.563-578, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 6
  • Publication Date: 2017
  • Doi Number: 10.1007/s13402-017-0351-7
  • Journal Name: CELLULAR ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.563-578
  • Keywords: AKR1B1, AKR1B10, Colorectal cancer, Inflammation, Motility, Prognosis, NF-KAPPA-B, BREAST-CANCER, CELL-PROLIFERATION, INHIBITION, EXPRESSION, GROWTH, IDENTIFICATION, INFLAMMATION, METASTASIS, TRANSITION
  • Middle East Technical University Affiliated: Yes

Abstract

Aldo-keto reductases (including AKR1B1 and AKR1B10) constitute a family of oxidoreductases that have been implicated in the pathophysiology of diabetes and cancer, including colorectal cancer (CRC). Available data indicate that, despite their similarities in structure and enzymatic functions, their roles in CRC may be divergent. Here, we aimed to determine the expression and functional implications of AKR1B1 and AKR1B10 in CRC.